Advances Is Mesenchymal Stem Cell Application for Cardiovascular Disease Treatment
Novel strategies are developed to optimize MSC function. Among them genetic modification is a promising solution to improve cell survival/engraftment after transplantation as well as to enhance cardioprotective function. Following genetic modification are
- PDF / 472,282 Bytes
- 36 Pages / 439.37 x 666.142 pts Page_size
- 43 Downloads / 210 Views
Advances Is Mesenchymal Stem Cell Application for Cardiovascular Disease Treatment
Abstract Novel strategies are developed to optimize MSC function. Among them genetic modification is a promising solution to improve cell survival/engraftment after transplantation as well as to enhance cardioprotective function. Following genetic modification are described: Bcl-2, CREG, Hsp20, Akt, PI3K-2a, ILK, periostin, CXCR4, TNFR, Ang1, VEGF, Wnt11. HO-1, GSK-3b, IGF-1, SDF-1, GATA-4. Pharmacological optimization or preconditioned media are also investigated to overcome current limitation in stem cell therapy. Pharmacological agent pretreatment strategy covered in this chapter includes application of diazoxide, estradiol, lysophosphatidic acid, lovastatin, oxytocin, phorbol myristate acetate, tadalafil, trimetazidine. Cytokine and growth factor pretreatment discussed below includes stromal-derived factor 1 alpha, angiopoietin-1, insulin-like growth factor-1, transforming growth factor-a, bone morphogenetic protein-2, fibroblast growth factor-2 and insulin-like growth factor-1 cocktail, interleukin-1b and transforming growth factor-b combination. Moreover, application of including injectable hydrogels are presented including cell containing injectable biomaterials, acellular scaffolds with incorporated bio-agents, and co-application of cells and bio-agents. Keywords Mesenchymal stem cells Pharmacologically optimized stem cells
1.1
Genetically modified Injectable hydrogels
stem cells
Genetically Modified Mesenchymal Stem Cells
Combined stem cell and gene therapy represents a novel and promising approach to treat heart diseases. It has been shown that genetic modifications of mesenchymal stem cells (MSCs) can improve survival and engraftment of transplanted MSCs and their cardioprotective effect against post-ischemic myocardial dysfunction [1]. The latter one can be achieved e.g. by the use of MSCs overexpressing genes encoding proteins that promote angiogenesis. Genetically modified MSCs represent a wide group of cells. Here we categorized them based on the primary effect of genetic modification on MSC transplantation © The Author(s) 2017 T. Jadczyk et al., Innovative Diagnostics and Treatment: Nanorobotics and Stem Cells, Nanotheranostics, DOI 10.1007/978-981-10-4527-1_1
1
2
1 Advances Is Mesenchymal Stem Cell Application …
and MSC function in cardiac repair. Specifically, MSCs overexpressing proteins that improve MSC survival and engraftment as well as factors that enhance MSC differentiation and their angiogenic potential are discussed (Fig. 1.1).
1.1.1
Genetically Modified MSCs with Improved Survival and Engraftment After Transplantation
Many different overexpressed genes have been employed in MSCs to improve their survival and engraftment after transplantation. Here we briefly describe MSCs overexpressing Bcl-2, CREG, Hsp20, Akt, PI3K-2a, ILK, periostin, CXCR4, TNFR. We discuss the effect of these genetic modifications on MSC transplantation and their use to increase efficacy of MSC-based therapy in heart disease tre
Data Loading...
